IL166040A0 - Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy - Google Patents

Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Info

Publication number
IL166040A0
IL166040A0 IL16604003A IL16604003A IL166040A0 IL 166040 A0 IL166040 A0 IL 166040A0 IL 16604003 A IL16604003 A IL 16604003A IL 16604003 A IL16604003 A IL 16604003A IL 166040 A0 IL166040 A0 IL 166040A0
Authority
IL
Israel
Prior art keywords
treatment
compounds useful
diseases responsive
diseases
antiangiogenetic
Prior art date
Application number
IL16604003A
Other languages
English (en)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of IL166040A0 publication Critical patent/IL166040A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16604003A 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy IL166040A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11
PCT/DK2003/000518 WO2004012733A2 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Publications (1)

Publication Number Publication Date
IL166040A0 true IL166040A0 (en) 2006-01-15

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16604003A IL166040A0 (en) 2002-08-01 2003-07-31 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy

Country Status (17)

Country Link
US (1) US20060058395A1 (zh)
EP (1) EP1526851B1 (zh)
JP (1) JP2005537336A (zh)
KR (1) KR20050026091A (zh)
CN (1) CN1671378A (zh)
AT (1) ATE372770T1 (zh)
AU (1) AU2003260280A1 (zh)
BR (1) BR0312929A (zh)
CA (1) CA2493253A1 (zh)
DE (1) DE60316297T2 (zh)
IL (1) IL166040A0 (zh)
IS (1) IS7723A (zh)
MX (1) MXPA05001235A (zh)
NO (1) NO20051074L (zh)
NZ (1) NZ537809A (zh)
PL (1) PL375318A1 (zh)
WO (1) WO2004012733A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004017175D1 (de) 2003-06-17 2008-11-27 Neurosearch As Diphenylurea-derivative und ihre verwendung als chloridkanalblocker
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2006085302A2 (en) * 2005-02-08 2006-08-17 Bmz Diagnosis (2004) Ltd. Composition for treatment of skin disorders
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
KR20080027890A (ko) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 혈전성 증상의 치료에 유용한 ｐ2ｙ1 수용체의 ｎ-연결헤테로시클릭 길항제
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
EP3458052B1 (en) 2016-05-17 2019-11-06 Scandion Oncology A/S Combination treatment of cancer
EP3846802A1 (en) * 2018-09-06 2021-07-14 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998047879A1 (en) * 1997-04-22 1998-10-29 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
WO1999032436A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
AP2001002103A0 (en) * 1998-10-22 2001-03-31 Neurosearch As Substituted phenyl derivatives, their preparation and use.
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos

Also Published As

Publication number Publication date
WO2004012733A9 (en) 2005-03-10
DE60316297T2 (de) 2008-06-19
ATE372770T1 (de) 2007-09-15
US20060058395A1 (en) 2006-03-16
CA2493253A1 (en) 2004-02-12
EP1526851A2 (en) 2005-05-04
IS7723A (is) 2005-03-01
NZ537809A (en) 2007-05-31
MXPA05001235A (es) 2005-06-08
CN1671378A (zh) 2005-09-21
EP1526851B1 (en) 2007-09-12
WO2004012733A2 (en) 2004-02-12
WO2004012733A3 (en) 2004-03-18
BR0312929A (pt) 2005-07-12
DE60316297D1 (de) 2007-10-25
NO20051074L (no) 2005-04-29
AU2003260280A1 (en) 2004-02-23
PL375318A1 (en) 2005-11-28
JP2005537336A (ja) 2005-12-08
KR20050026091A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
IS7723A (is) Efnasambönd sem eru gagnleg til meðhöndlunar á sjúkdómum sem svara meðferð sem bælir æðamyndun
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
AU2003276028A1 (en) Pyridine derivatives as cb2 receptor modulators
AU2002341920A1 (en) Chemical compounds
NO2010020I2 (zh)
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
MXPA04004064A (es) Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
UA85559C2 (en) Aminobenzophenone compounds
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
ME01486B (me) Novi pirolo [3, 2-d)pirimidin-4-on derivati i njihova primjena u terapiji
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
MY149492A (en) Immunoglobulins directed against nogo
WO2003051886A8 (en) Pyrazolopyridazine derivatives
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
AU2003260436A1 (en) Pyrimidine compounds
WO2004009064A8 (de) Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
WO2004084809A3 (en) Neuroprotective macrocylic compounds and methods for their use
EP1436279B8 (en) Chemical compounds
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
UA81420C2 (en) Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase